UBE2: A Potential Drug Target for Many Diseases (G27338)

Target Name: UBE2S

NCBI ID: G27338

UBE2S

UBE2: A Potential Drug Target for Many Diseases

Ubiquitin-conjugating enzyme E2 (UBE2) is a protein that plays a crucial role in the regulation of protein degradation in the cell. It is a member of the superfamily of ubiquitin enzymes, which include 21 different proteins that share a conserved catalytic core but differ in their specificity for different target proteins. UBE2 is involved in the degradation of a wide variety of proteins, including proteins involved in cell signaling, development, and infection.

Recent studies have identified UBE2 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because UBE2 is a key enzyme in the degradation of many of the proteins that are implicated in these diseases, and drugs that can inhibit its activity may have therapeutic benefits.

One of the reasons why UBE2 is considered a potential drug target is its involvement in the regulation of protein degradation. Many diseases are characterized by the accumulation of misfolded or misfolded proteins, which can have harmful effects on the cell. UBE2 is involved in the degradation of these misfolded proteins, which may help to prevent their accumulation and contribute to the development of disease.

Another potential drug target for UBE2 is its role in the regulation of cell signaling. Many proteins involved in cell signaling are targeted for degradation by UBE2, and inhibiting this activity may be a way to treat diseases that are caused by the overproduction or dysfunction of these proteins. For example, UBE2 has been shown to be involved in the regulation of the protein known as Tau, which is involved in the development of Alzheimer's disease. Tau is often targeted for degradation by UBE2, and inhibiting its activity may be a way to treat this disease.

UBE2 is also involved in the regulation of cell division and apoptosis, which are important processes that are involved in the development and progression of many diseases. In addition, UBE2 is involved in the regulation of inflammation, which is another important aspect of disease development.

In conclusion, UBE2 is a protein that plays a crucial role in the regulation of protein degradation and is a potential drug target for a variety of diseases. The inhibition of UBE2 activity may be a promising new approach to the treatment of these diseases. Further research is needed to fully understand the role of UBE2 in disease and to develop effective treatments.

Protein Name: Ubiquitin Conjugating Enzyme E2 S

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:22496338). Catalyzes 'Lys-11'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by specifically elongating 'Lys-11'-linked polyubiquitin chains initiated by the E2 enzyme UBE2C/UBCH10 on APC/C substrates, enhancing the degradation of APC/C substrates by the proteasome and promoting mitotic exit (PubMed:19820702, PubMed:19822757, PubMed:27259151). Also acts by elongating ubiquitin chains initiated by the E2 enzyme UBE2D1/UBCH5 in vitro; it is however unclear whether UBE2D1/UBCH5 acts as an E2 enzyme for the APC/C in vivo. Also involved in ubiquitination and subsequent degradation of VHL, resulting in an accumulation of HIF1A (PubMed:16819549). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, except 'Lys-48'-linked polyubiquitination (PubMed:20061386, PubMed:20622874)

The "UBE2S Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2S comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets